Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common inherited enzyme conditions in the world, and patients who have it are routinely warned about a family of antimalarial drugs that can trigger dangerous red blood cell breakdown. But not all of these drugs carry the same risk. This article explains, in plain terms grounded in the actual pharmacology, why hydroxychloroquine sits in a meaningfully lower-risk category than primaquine, and why it is generally regarded as intermediate-to-low risk compared with chloroquine as well. The goal is not to dismiss caution but to replace vague warnings with an accurate picture, so that patients and their physicians can make informed decisions together.

What G6PD Deficiency Actually Does to a Red Blood Cell

G6PD is the enzyme that starts a chain reaction inside red blood cells producing NADPH, which in turn keeps a molecule called glutathione in its reduced, protective form. Reduced glutathione is the cell's main defense against oxidative stress. Red blood cells have no nucleus and cannot manufacture new enzyme once they are in circulation, so when G6PD activity is low, older cells gradually lose their ability to neutralize oxidative damage. Under normal daily life this rarely matters. Under a strong oxidative challenge — certain infections, fava beans, or certain drugs — hemoglobin inside the cell can oxidize and precipitate, the cell membrane is damaged, and the spleen removes these damaged cells rapidly. That process is hemolysis.

G6PD deficiency is X-linked, so it is more common and typically more severe in males, while women can have a mosaic pattern of normal and deficient cells due to random X-inactivation. The World Health Organization has estimated it affects several hundred million people globally, with the highest frequencies in populations with ancestry from Africa, the Mediterranean basin, the Middle East, and parts of Southeast Asia. This is not a random defect — it persisted in these populations because carrying one deficient copy offers partial protection against severe malaria, a sobering but real example of how the body's variation, even its vulnerabilities, can carry embedded purpose within a fallen and disease-burdened world. Not all G6PD variants are equal: the Mediterranean variant produces markedly lower enzyme activity than the common African A- variant, which is one reason a family history or known ancestry is clinically useful information, not just genealogy.

Why Primaquine Is the Classic Trigger

Primaquine belongs to a chemical class called 8-aminoquinolines, along with the newer drug tafenoquine. These drugs are metabolized into reactive quinoline-quinone compounds that directly cycle electrons within the red blood cell, generating hydrogen peroxide and other oxidative species essentially inside the cell itself. This redox-cycling activity is intrinsic to the 8-aminoquinoline structure and its metabolites, and it is potent enough that even people with only mild G6PD variants can experience clinically significant hemolysis, particularly during the longer 14-day "radical cure" courses used to prevent relapse of Plasmodium vivax malaria.

Because this risk is well established through decades of clinical experience and confirmed in pharmacologic studies, both the World Health Organization and the U.S. Centers for Disease Control and Prevention recommend G6PD enzyme testing before starting primaquine or tafenoquine for radical cure regimens. The FDA label for both drugs explicitly requires G6PD testing prior to use. A single low dose of primaquine used only to reduce malaria transmission (rather than for relapse prevention) carries a smaller cumulative oxidative exposure and is now considered acceptable by WHO even without testing in most settings, but the multi-day radical cure regimen is a different matter entirely. This is the benchmark against which chloroquine and hydroxychloroquine are often — somewhat unfairly — lumped together in casual references.

Chloroquine: A Genuinely Intermediate Case

Chloroquine is a 4-aminoquinoline, a different ring-substitution pattern from primaquine's 8-aminoquinoline structure, and this difference in chemistry matters enormously. Chloroquine and its metabolites do not undergo the same intense redox-cycling within the red cell. Clinical and pharmacovigilance experience over more than 70 years of use has shown that chloroquine carries a real but comparatively modest hemolysis risk in G6PD-deficient patients — one that is dose- and variant-dependent, and generally milder and less predictable than what is seen with primaquine. Some pharmacology references list chloroquine as a drug to use with caution or at reduced dose in G6PD deficiency rather than one that is strictly contraindicated, and routine pre-treatment G6PD testing has not become a standard requirement for chloroquine the way it has for primaquine and tafenoquine. Still, because malaria treatment doses of chloroquine are relatively high and given over a short period, caution is warranted, and clinicians treating known G6PD-deficient patients often monitor more closely or consider alternatives when available.

Hydroxychloroquine's Distinct Position

Hydroxychloroquine is a close chemical cousin of chloroquine — it is essentially chloroquine with a hydroxyl group added to the side chain — but this modification changes both its pharmacokinetics and its clinical risk profile. Hydroxychloroquine is metabolized more slowly, is used chronically at lower daily doses in autoimmune disease (typically 200–400 mg per day for lupus or rheumatoid arthritis, versus the higher bolus doses used for acute malaria treatment), and its oxidative potential in red blood cells appears lower still than chloroquine's in the available data.

The clinical evidence here is best described honestly as reassuring but not exhaustive. Hydroxychloroquine has been used for decades in very large numbers of lupus and rheumatoid arthritis patients worldwide, including in regions where G6PD deficiency is common, without hemolytic crisis emerging as a prominent signal in rheumatology practice or in pharmacovigilance databases. Isolated case reports do exist in the medical literature describing mild, self-limited hemolysis in G6PD-deficient patients taking hydroxychloroquine, and these are worth taking seriously as individual clinical events, but they have not translated into a population-level pattern that changed prescribing guidelines. The American College of Rheumatology does not mandate G6PD testing before starting hydroxychloroquine, and the FDA prescribing information notes G6PD deficiency as a condition warranting monitoring for hemolytic anemia rather than an absolute contraindication. This is a meaningfully different regulatory posture than the explicit pre-treatment testing requirement attached to primaquine and tafenoquine.

It is worth being precise about what "lower risk" does and does not mean. It does not mean zero risk. It means that across the chemical class, the dosing pattern, and decades of accumulated clinical experience, hydroxychloroquine has not demonstrated the same reliable, dose-related hemolytic signal that primaquine does. Some of this difference is well explained mechanistically by the 4-aminoquinoline versus 8-aminoquinoline chemistry; some of it may also reflect the fact that hydroxychloroquine's typical dosing in chronic disease is simply gentler on the red cell than a malaria treatment or radical-cure course.

What This Means for Patients and Physicians

None of this is an argument for skipping conversation with your physician if you know or suspect you have G6PD deficiency. It is an argument for precision. A patient starting a 14-day primaquine course for vivax malaria relapse prevention is in a fundamentally different risk category than a lupus patient starting long-term hydroxychloroquine, and both deserve to understand why, rather than being handed an identical blanket warning.

This is where informed consent and personal responsibility meet good medicine. Knowing your own or your child's G6PD status, understanding your family's ancestry-linked risks, and asking direct questions about why a particular drug is or is not being recommended are all part of stewarding a body that was fashioned with real complexity and real vulnerability. A physician who takes the time to distinguish primaquine's known hemolytic potency from hydroxychloroquine's much milder record is giving you the tools to make a genuinely informed decision rather than a fear-based one.

Key takeaway: Hydroxychloroquine's chemical structure and typical dosing give it a substantially lower and less predictable hemolysis risk in G6PD deficiency than primaquine, and a somewhat lower risk than chloroquine, but it still warrants monitoring rather than casual disregard — a distinction worth discussing directly with your own physician.